CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer

Int J Cancer. 2002 Sep 10;101(2):196-7. doi: 10.1002/ijc.10590.

Abstract

We have combined data from case control studies designed to test the hypothesis that the c-160a promotor polymorphism in the gene coding for the cell adhesion molecule E-cadherin (CDH1) is associated with stomach cancer. A total of 899 individuals (433 patients and 466 controls) were analyzed. The genotype frequencies did not differ significantly between cases and controls, and the genotype-specific risks were not significantly different from unity, with an odds ratio for heterozygotes compared with the common homozygote of 1.3 (95% CI 0.98-1.8) and 1.2 (0.68-2.0) for rare homozygotes compared with common homozygotes. We found no evidence for differences in risk for the intestinal- and diffuse-type histopathologic subgroups.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Cadherins / genetics*
  • Canada
  • Female
  • Gene Frequency
  • Genetic Predisposition to Disease*
  • Germany
  • Humans
  • Male
  • Middle Aged
  • Odds Ratio
  • Polymorphism, Genetic / genetics*
  • Portugal
  • Promoter Regions, Genetic / genetics*
  • Stomach Neoplasms / etiology
  • Stomach Neoplasms / genetics*

Substances

  • Cadherins